U.S. markets open in 1 hour
  • S&P Futures

    4,396.00
    -7.00 (-0.16%)
     
  • Dow Futures

    34,880.00
    -71.00 (-0.20%)
     
  • Nasdaq Futures

    15,075.75
    -22.25 (-0.15%)
     
  • Russell 2000 Futures

    2,209.00
    +3.90 (+0.18%)
     
  • Crude Oil

    71.94
    -0.13 (-0.18%)
     
  • Gold

    1,805.10
    +3.30 (+0.18%)
     
  • Silver

    25.35
    +0.12 (+0.48%)
     
  • EUR/USD

    1.1791
    +0.0021 (+0.18%)
     
  • 10-Yr Bond

    1.2860
    0.0000 (0.00%)
     
  • Vix

    18.33
    +0.64 (+3.62%)
     
  • GBP/USD

    1.3789
    +0.0035 (+0.26%)
     
  • USD/JPY

    110.3630
    -0.1470 (-0.13%)
     
  • BTC-USD

    38,731.15
    +4,384.39 (+12.77%)
     
  • CMC Crypto 200

    926.94
    +133.20 (+16.78%)
     
  • FTSE 100

    7,021.01
    -6.57 (-0.09%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

Processa Pharmaceuticals In-Licenses Ocuphire's Anticancer Agent

·1 min read
  • Processa Pharmaceuticals Inc (NASDAQ: PCSA) has entered into a licensing agreement with Ocuphire Pharma Inc (NASDAQ: OCUP) to in-license RX-3117.

  • RX-3117 is an oral anticancer agent with an improved pharmacological profile relative to gemcitabine and other nucleoside analogs.

  • Rx-3117 has a family of patents extending into 2036 and FDA Orphan Designation to treat Pancreatic Cancer.

  • Processa will evaluate the potential benefit of RX-3117 for patients with such cancers as pancreatic or non-small cell lung cancer.

  • Under the terms of the agreement, Processa has an exclusive worldwide license (excluding China) to develop, manufacture, use, commercialize and sublicense RX-3117.

  • Processa will be developing biomarker assays to identify those patients who will most likely benefit from this targeted therapy.

  • The First Phase 2b trial to assess the correlation of the biomarker measurements with the clinical benefit-risk of RX-3117 will start in 2022.

  • Price Action: OCUP shares are down 3.3% at $4.84, and PCSA shares are down 0.3% at $6.45 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.